The agenda includes:
Preparation of evaluation positions:
- Apexxnar, pneumococcal polysaccharide conjugated vaccine (20-valent, adsorbed) for the indication: prevention of pneumococcal infections in adults over 65 years of age,|
- Lorviqua (lorlatinib) under the drug programme “First-line treatment of non-small cell lung cancer with lorlatinib (ICD-10 C 34)”.
Preparing an opinion on the legitimacy of introducing changes in the current description of the B.90 drug programme: “Treatment of motor impairment in advanced Parkinson’s disease (ICD-10 G.20)”.
Preparation of an opinion on the inclusion in the reimbursement procedure of drugs containing the active substance stiripentol for the indication: malignant focal migratory epilepsy of infants.